No Data
No Data
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and VolitionRX (VNRX)
VolitionRx Limited to Present at Jefferies Global Healthcare Conference
VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announced today that Cameron Reynolds, President and...
VolitionRX Price Target Maintained With a $2.50/Share by Cantor Fitzgerald
VolitionRX Price Target Maintained With a $2.50/Share by Cantor Fitzgerald
Cantor Fitzgerald Reiterates Overweight on VolitionRX, Maintains $2.5 Price Target
Cantor Fitzgerald analyst Ross Osborn reiterates VolitionRX with a Overweight and maintains $2.5 price target.
VolitionRX (VNRX) Receives a Buy From Cantor Fitzgerald
Earnings Call Summary | VolitionRX(VNRX.US) Q1 2024 Earnings Conference
The following is a summary of the VolitionRx Limited (VNRX) Q1 2024 Earnings Call Transcript:Financial Performance:VolitionRx reported Q1 revenue of approximately $170,000, a 15% increase compared to
No Data